@nicogagelmann.bsky.social shares findings that longer telomeres in donors ≥35 are associated with reduced graft failure and lower non-relapse mortality following allogeneic HCT. #ASH25

Don't get left out at sea! Prepare now for ASH-a-Palooza at #ASH25🐬

◽Sign up early for Blood Buddy speed mentoring: https://ow.ly/Cafw50XA6Gt

◽Arrive by 11:45 a.m. for the Global Hematology Trainee Networking Lunch

◽Join the AAP treasure hunt ( in the #ASH25 app)

#ASHTrainee ASH Education

The #ASH25 virtual platform is now live! Log in now using the ASH username and password you used to register for the annual meeting: https://ow.ly/MmlR50XBiMT

🌟Your bonus and preview content await. Plus, explore networking, exhibits, and more on the virtual platform! #HemeSky #MedSky

Your go-to social media guide for #ASH25 is here. Find tips on following updates, taking part in conversations, using the official hashtags, and entering fun challenges with #ASHNewsDaily.

Read now: https://ow.ly/tEgJ50XxAP6

#HemeSky #ASHaiku #ASHKudos #ASHRunWalk #ASHScavengerHunt

The ASH annual meeting is the premier venue for #hematology collaborations across borders 🌏

#ASHThrowback to a meeting with ASH and the Mediterranean Partner Societies at #ASH24. Belinda Avalos, MD #ASH25

International community, share your throwbacks from past ASH meetings! #HemeSky

Finally in Boston!

Honored to join @danafarber.bsky.social, eager to learn and contribute in this terrific community @coleman-lindsley.bsky.social.

A place of science, purpose and hope.

Thank you all who made COSTEM 2025 THE event for transplant & cellular therapies❗️

Faculty who fight REAL debates

Audience that ask REAL questions

Unity amid controversy🙏

See you 1-3 October 2026 in Berlin again!

Registration - COSTEM Congress 2025 Registration for COSTEM 2025

Last Call for Early Bird Registration

Join us at the 10th COSTEM Congress!

🗓️ September 25–28, 2025
📍 Berlin, Germany

Don't miss your chance to save – Early Bird registration closes July 31st!
costem.cme-congresses.com/registration/

🎥 Check out our recent interview from #CART25 with @nicogagelmann.bsky.social, in which he highlights the need to address inequality & inequity in access to #CARTCell therapy across Europe:

👉 buff.ly/4gBhWeD

#ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky

Out now in Blood Advances 🙌🏽

Our work from Princess Margaret Cancer Centre evaluating the role of PTCy in matched sibling donor allogeneic transplantation!

Also read this excellent commentary by my good friend @nicogagelmann.bsky.social 👇🏽

ashpublications.org/bloodadvance...

MAKE CAR-T AFFORDABLE AGAIN

Terrific learning experience from cellular therapy programs in India, Slovenia, Brazil and Turkey

#CART25

Let's learn hematology in 2025🩸

Day 27: hemophilia characteristics

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Levera...

🎉Finally published🎉

Cilta-cel vs ide-cel for relapsed or refractory multiple myeloma

@hemasphere-journal.bsky.social

onlinelibrary.wiley.com/doi/full/10....

Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...

🎉Finally published🎉

Clearance of driver mutations after transplantation for myelofibrosis

@nejm.org

www.nejm.org/doi/full/10....

Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...

In a single-group, single-center study, clearance of driver mutations 30 days after bone marrow transplantation predicted long-term disease-free survival in patients with myelofibrosis. Read the full study results: nej.md/4fQNdKn

#MedSky

Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...

www.nejm.org/doi/full/10....

Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY

Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn

Thanks Anand!!

a blockbuster paper by @nicogagelmann.bsky.social et al in @nejm.org on the impact of driver mutation clearance in patients with MF that underwent allo-HCT!

www.nejm.org/doi/full/10....

Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...

🎉Finally published🎉

Clearance of driver mutations after transplantation for myelofibrosis

@nejm.org

www.nejm.org/doi/full/10....

@nicogagelmann.bsky.social

#ASHKudos for the award. Glad that you had fun at #ASH24!

What a wonderful #ASH24

Honored to receive @ash-hematology.bsky.social Abstract Achievement Award, meet friends, celebrate colleagues' achievements, enjoy terrific science and San Diego.

Until next year 🙏🩸❤️

Tomorrow @nicogagelmann.bsky.social will take over our Twitter account, bringing you live updates & expert takes straight from #ASH24 🗞️🩸📱

Give us a follow over there so you don't miss the action 👉 x.com/VJHemOnc 👀

Now @nicogagelmann.bsky.social on molecular genetics and JAKi impact on allo-HCT in MF
-1800 rux treated pts
-early allo in high-risk PMF and SMF seems to be best timing
-early allo in TP53 may offer survival benefit

🎉Finally out and timely for #ASH24 @ash-hematology.bsky.social 🎉

Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple #myeloma #mmsm

t.co/F7QjOoavKO

Happy to present first European comparison of cilta-cel vs ide-cel for #myeloma #ASH24:

-Cilta-cel with better ORR, CR, PFS
-Similar NRM
-Peak CAR-T expansion day 14 for cilta-cel vs day 7 for ide-cel
👉associated with response and with ICANS for cilta-cel
@ash-hematology.bsky.social

Honored to be featured on the @ash-hematology.bsky.social ASH News Daily #ASH24 follow list! I'll be posting on both my Twitter (https://buff.ly/3Zy7BLc and BS (https://buff.ly/3B9SpKU so please do follow! https://buff.ly/49iWb1d

cc @rahulbanerjeemd.bsky.social @shematologist.bsky.social @nicogagelmann.bsky.social